Evolent Health, Inc (EVH) Shares Bought by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC raised its holdings in Evolent Health, Inc (NYSE:EVH) by 552.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,295 shares of the technology company’s stock after buying an additional 52,746 shares during the period. Parametric Portfolio Associates LLC owned about 0.10% of Evolent Health worth $1,579,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in EVH. FMR LLC raised its stake in Evolent Health by 117.7% in the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock valued at $250,073,000 after buying an additional 5,333,252 shares during the period. Riverbridge Partners LLC bought a new stake in Evolent Health in the second quarter valued at approximately $58,878,000. Vanguard Group Inc. raised its stake in Evolent Health by 48.9% in the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock valued at $95,566,000 after buying an additional 1,237,941 shares during the period. Eagle Asset Management Inc. bought a new stake in Evolent Health in the second quarter valued at approximately $27,577,000. Finally, Wells Fargo & Company MN raised its stake in Evolent Health by 728.9% in the second quarter. Wells Fargo & Company MN now owns 759,724 shares of the technology company’s stock valued at $19,259,000 after buying an additional 668,066 shares during the period. Hedge funds and other institutional investors own 92.74% of the company’s stock.

Shares of Evolent Health, Inc (EVH) opened at $11.15 on Monday. Evolent Health, Inc has a 12-month low of $10.35 and a 12-month high of $27.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. The business had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The firm’s quarterly revenue was up 79.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.26) earnings per share. analysts anticipate that Evolent Health, Inc will post -0.57 earnings per share for the current year.

WARNING: “Evolent Health, Inc (EVH) Shares Bought by Parametric Portfolio Associates LLC” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://weekherald.com/2017/11/13/evolent-health-inc-evh-shares-bought-by-parametric-portfolio-associates-llc.html.

EVH has been the topic of several research reports. BidaskClub downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Cowen and Company reaffirmed an “outperform” rating and issued a $29.00 target price (down previously from $33.00) on shares of Evolent Health in a research report on Friday, October 6th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $30.00 target price on shares of Evolent Health in a research report on Friday, November 3rd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of Evolent Health in a research report on Wednesday, September 6th. Finally, ValuEngine downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company’s stock. Evolent Health currently has an average rating of “Buy” and an average price target of $28.70.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply